“Blood-brain barrier permeable β-blockers association with Alzheimer’s disease cerebrospinal fluid biomarkers levels in non-demented individuals”

Authors:  
Mariateresa Buongiorno, Gonzalo Sánchez-Benavides, Clara Marzal-Espí, Darly Milena Giraldo, Jerzy Krupinski, Natalia Cullell, Oriol Grau-Rivera, Marc Suárez-Calvet, Juan Domingo Gispert, Alex de la Sierra, and for the Alzheimer’s Disease Neuroimaging Initiative, and the European Prevention of Alzheimer’s Disease (EPAD) Consortium

Abstract:

β-blockers that easily cross the blood-brain barrier (BBB) seem to diminish the risk of Alzheimer’s disease (AD), hypothetically facilitating waste clearance. However, their effect on AD pathophysiological markers is unknown. We compared cerebrospinal fluid (CSF) AD biomarker levels among non-demented individuals taking low, intermediate, or high BBB permeable β-blockers in two samples (ADNI: n = 216; EPAD: n = 79). We found that CSF amyloid-β levels were higher in individuals taking highly permeable β-blockers in the ADNI sample. This result was not replicated in EPAD, in which diminished levels of pTau181 and tTau were observed. These data suggest that β-blockers may impact AD pathophysiology.

DOI: https://doi.org/10.1177/13872877241293812

Published online: 25 November 2024 in SAGEJournals